Skip to main content
. Author manuscript; available in PMC: 2011 May 15.
Published in final edited form as: Cancer Res. 2010 Apr 20;70(10):3945–3954. doi: 10.1158/0008-5472.CAN-09-4480

Figure 5.

Figure 5

SA-4-1BBL conjugate vaccine has robust efficacy in eradicating established 3LL tumors. C57BL/6 mice were challenged with 3LL tumor cells and vaccinated s.c. on day 6 post-tumor challenge with survivin (10 μg) conjugated or nonconjugated with SA-4-1BBL (25 μg) or an equimolar quantity of SA (10 μg). ** P < 0.001 for conjugated SA-4-1BBL-survivin vs. all other groups.